Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL992409 | 0.89 | PDE3A (0.57) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL15197941 | 0.84 | POLA1 (0.48) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL992637 | 0.83 | P2RY2 (0.44) | POLA1CYP2C19 | |
| SCHEMBL9798551 | 0.82 | PDE3A (0.66) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL9798561 | 0.82 | PDE3A (0.66) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL23724058 | 0.82 | PDE3A (0.66) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL15197943 | 0.81 | PDE4D (0.62) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL21849051 | 0.81 | PDE4D (0.63) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| SCHEMBL17770788 | 0.80 | PDE3A (0.62) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 | |
| Gemcitabine Elaidate SCHEMBL582034 | 0.79 | PDE4D (0.56) | POLA1PDE4DPDE3ASLC29A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120142101-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | RNGTT, POLRMT, POLM | POLA1 63/4885PDE4D 1492/4885PDE3A 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.